前列腺癌风险随年龄增长升高，专家建议50岁以上男性定期筛查

Core Insights - Prostate cancer is the most common newly diagnosed cancer among male urogenital tumors in China, with an annual incidence of 134,200 cases, and both incidence and mortality rates are increasing year by year [2] Group 1: Disease Overview - Prostate cancer poses a significant threat to the physical and mental health of middle-aged and elderly men, with the risk of developing the disease increasing with age [2][3] - Regular PSA (Prostate-Specific Antigen) screening is recommended for men over 50, and for those with a family history of prostate cancer, screening should begin at 45 [2][3] Group 2: Treatment and Prognosis - The early detection of prostate cancer through standardized PSA screening has led to a higher rate of clinical cures among early-stage patients, although over 30% of patients are diagnosed with distant metastasis at the time of diagnosis, resulting in poor overall prognosis [2] - New endocrine therapies and targeted drugs are emerging, significantly improving patient survival rates and quality of life [2][3] Group 3: Monitoring and Quality of Life - In the evaluation of advanced prostate cancer treatment, a rapid and deep decline in PSA levels is a key indicator of good prognosis [3] - Patients receiving new endocrine treatments who achieve a PSA level below 0.2 ng/mL within three months have significantly better progression-free survival and overall survival compared to those with insufficient PSA decline [3] - Effective treatment and care can lead to improved quality of life for advanced prostate cancer patients, supported by family, medical staff, and societal support [3]